| [1] |
Sukonthasarn A. A comparison of four primary classes of antihypertensive monotherapy in Thai patients[J]. J Med Assoe Thai, 2000, 83(10): 1202-1210.
|
| [2] |
Gonzalez FJ,Idle JR.Pharmacogenetic phenotyping and genotyping.Present status and future potential[J]. Clin Pharmacokinet, 1994, 26(1): 59-70.
|
| [3] |
Rioux PP.Clinial trials in pharmacogenetics and pharmacogenomies：methods and applications[J]. Am J Health Syst Pharm, 2000, 57(9): 887-898.
|
| [4] |
Lamba JK,Lin YS,Schuetz EG, et al.Genetic contribution to variable human CYP3A-mediated metabolism[J]. Adv Drug Deliv Rev, 2002, 54(10): 1271-1294.
|
| [5] |
Terrazzino S,Quaglia M,Stratta P, et al.The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis[J]. Pharmacogenet Genom, 2012, 22(8): 642-645.
|
| [6] |
Gellner K,Eiselt R,Hustert E, et al.Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene[J]. Pharmacogenetics, 2001, 11(2): 111-121.
|
| [7] |
Yamaori S,Yamazaki H,Suzuki A, et al.Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7[J]. Biochem Pharmacol, 2003, 66(12): 2333-2340.
|
| [8] |
杨策,王海燕,杜娟, 等. 精准医学思维对创伤诊治模式的影响与前景[J/CD]. 中华诊断学电子杂志, 2015, 3(2): 98-101.
|
| [9] |
Koch I,Weil R,Wolbold R, et al.Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA[J]. Drug Metab Dispos, 2002, 30(10): 1108-1114.
|
| [10] |
Tateishi T,Watanabe M,Moriya H, et al.No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins[J]. Biochem Pharmacol, 1999, 57(8): 935-939.
|
| [11] |
Huang W,Lin YS,Calamia J C, et al.Evidence of significant contribution from CYP3A5 to hepatic drug metabolism[J]. Drug Metab Dispos, 2004, 32(12): 1434-1445.
|
| [12] |
Saeki M,Saito Y,Nakamura T, et al.Single nucleotide polymorphisms and haplotype frequencies of CYP3A5, in a Japanese population[J]. Hum Mut, 2003, 21(6): 653-660.
|
| [13] |
Kamide K,Yang J,Matayoshi T, et al.Genetic polymorphisms of L-type calcium channel alpha1C and alpha1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyridine calcium-channel blockers[J]. Circ J, 2009, 73(4): 732-740.
|
| [14] |
Burk O,Koch I,Raucy J, et al.The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR)[J]. J Biol Chem, 2004, 279(37): 38379-38385.
|
| [15] |
Simpson D,Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions[J]. Drugs, 2005, 65(6): 827-858.
|
| [16] |
Langaee TY,Gong Y,Yarandi HN, et al.Association of CYP3A5 Polymorphisms with Hypertension and Antihypertensive Response to Verapamil[J]. Clin Pharmacol2007, 81(3): 386-391.
|
| [17] |
Motshoge T,Tawe L,Muthoga CW, et al.Cytochrome P450 2C8*2 allele in Botswana: human genetic diversity and public health implications[J]. Acta Trop, 2016, 157: 54-58.
|
| [18] |
Kuehl P,Zhang J,Lin Y, et al.Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J]. Nat Genet, 2001, 27(4): 383-391.
|
| [19] |
储小曼,闵佩清,张静, 等. 药物代谢酶CYP3A在中国肾移植人群的遗传多态性[J]. 医学研究生学报, 2005, 18(2): 107-111.
|
| [20] |
Yamaori S,Yamazaki H,Suzuki A, et al.Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7[J]. Biochem Pharmacol, 2003, 66(12): 2333-2340.
|
| [21] |
Fukushima-Uesaka H,Saito Y,Watanabe H, et al.Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population[J]. Hum Mutat, 2004, 23(1): 100.
|
| [22] |
Xie HG,Wood AJ,Kim RB, et al.Genetic variability in CYP3A5 and its possible consequences[J]. Pharmacogenomics, 2004, 5(3): 243-272.
|
| [23] |
Hu YF,He J,Chen GL, et al.CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population[J]. Clinica Chimica Acta, 2005, 353(1-2): 187-192.
|
| [24] |
Kim KA,Park PW,Lee OJ, etal.Effect of CYP3A5*3 genotype on the pharrnacokinetics and pharmacodynamics of in amlodipine in healthy Korean subjects[J]. Clin Pharmacol Ther, 2006, 80(6): 646-656.
|
| [25] |
Kim KA,Park PW,Lee OJ, et al.Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects[J]. J Clin Pharmacol, 2007, 47(1): 87-93.
|
| [26] |
文娟,黄志军,袁洪, 等. 肾移植后高血压人群中CYP3A4*1G、CYP3A5*3和MDR1 C3435T基因多态性对氨氯地平降压疗效的影响[J]. 中国动脉硬化杂志, 2011, 19(1): 55-60.
|
| [27] |
Zhao Y,Zhai D,He H, et al.Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort[J]. Eur J Clin Pharmacol, 2009, 65(6): 579-584.
|